Archive · 2 Jun 2025
Alembic Pharma Shares Rise After USFDA Approval for Blood Cancer Drug
Imagine a company called Alembic Pharma that makes medicine.
They just got permission from the US government to sell a new drug called Bosutinib, which helps people with a type of blood cancer.
The company's stock price went up a little bit because of this good news.
The drug has already been approved by other pharmaceutical companies and is known to make around $291 million.
Even though they got this approval, the company's profits went down a little bit in the last three months.
Overall, the company is doing well and have other drug approvals.
Alembic Pharma received USFDA approval for Bosutinib Tablets to treat blood cancer.
The drug is for patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).
The estimated market size for Bosutinib Tablets is $291 million.
Alembic Pharma's shares rose 1.1% after the announcement.
The company's Q4 profits fell by 11.8% year-on-year.
- Who
- Alembic Pharma, a pharmaceutical company, received the approval.
- What
- Alembic Pharma received USFDA approval for Bosutinib Tablets, a drug for treating blood cancer.
- When
- May 30, when the approval was announced, though the Q4 results were announced earlier in the month.
- Where
- The USFDA approval is for the United States market. The company is based in Vadodara.
- Why
- The USFDA approval is expected to boost sales of the drug, potentially increasing company revenue.
Alembic Pharma Performance
Market Outlook
Share Performance
Alembic Pharma Performance
Shares are down 3% year-to-date.
Market Outlook
The stock gained 16% in the last month and is up 1.1% today.
Profitability
Alembic Pharma Performance
Profits fell 11.8% year-on-year.
Market Outlook
Revenue rose by 16.7% year-on-year.
- Company
- Alembic Pharma Ltd.
- Drug Name
- Bosutinib Tablets
- Indication
- Blood cancer (Ph+ CML)
- Approval Agency
- USFDA
- Market Size
- $291 million (estimated)
- Share Change
- +1.1%
- Previous Approval
- Carbamazepine tablets (April 2024)
- Q4 Profit Decline
- 11.8%